Cescon, David
University Health Network
Novel cell-free DNA assays to predict relapse and guide systemic therapy in early breast cancer
|
2017/2018 : $150,000
2018/2019 : $150,000
2019/2020 : $150,000
|
Davey, Scott
Queen's University
A functional approach to assessing variants of unknown significance in BRCA1 carriers
|
2017/2018 : $150,000
2018/2019 : $150,000
2019/2020 : $150,000
|
Godbout, Roseline
University of Alberta
Targeting p53-mutated triple-negative breast cancer: role of nuclear factor IB
|
2017/2018 : $149,920
2018/2019 : $149,920
2019/2020 : $149,920
|
Gunning, Patrick
University of Toronto
Small molecules targeting aberrant STAT3 activity in breast cancer: killing breast tumour cells and inducing anti-tumour immune response
|
2017/2018 : $150,000
2018/2019 : $150,000
2019/2020 : $150,000
|
Johnston, Brent
Dalhousie University
Targeting breast cancer via combined natural killer T cell immunotherapy and oncolytic virotherapy
|
2017/2018 : $150,000
2018/2019 : $150,000
2019/2020 : $150,000
|
Khokha, Rama
University Health Network
Rationalized depletion of mammary progenitors as a program for breast cancer prevention
|
2017/2018 : $150,000
2018/2019 : $150,000
2019/2020 : $150,000
|
Kotsopoulos, Joanne
Women's College Hospital
Delineating a role of RANKL/OPG-signalling on breast cancer development
|
2017/2018 : $150,000
2018/2019 : $150,000
2019/2020 : $149,650
|
Lee, Jonathan
University of Ottawa
Control of breast cancer by cooperation between the PI4KIIIB lipid kinase and the Rab11a GTPase
|
2017/2018 : $150,000
2018/2019 : $150,000
2019/2020 : $149,919
|
Lohrisch, Caroline
BC Cancer Agency
LA LEAST. Luminal A, Limited Endocrine Adjuvant Systemic Therapy, a phase II trial of abbreviated hormone therapy for low risk hormone receptor positive, HER2 negative early breast cancer
|
2017/2018 : $150,000
2018/2019 : $150,000
2019/2020 : $150,000
|
Metcalfe, Kelly
University of Toronto
Breast cancer treatment in women with PALB2 mutations
|
2017/2018 : $149,071
2018/2019 : $146,637
2019/2020 : $149,481
|
Nielsen, Torsten
Vancouver General Hospital
Clinical utility of immune response biomarkers for aggressive breast cancers
|
2017/2018 : $149,343
2018/2019 : $149,848
2019/2020 : $149,446
|
Ross, Colin
University of British Columbia
Pharmacogenomic discovery of predictive cardiotoxicity biomarkers in breast cancer patients receiving anthracycline chemotherapies
|
2017/2018 : $148,942
2018/2019 : $147,353
2019/2020 : $148,230
|
Shepherd, Lois
Queen's University
Quantitative standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) for prognostic and/or predictive index for response to adjuvant aromatase inhibitors exemestane or anastrozole
|
2017/2018 : $59,300
2018/2019 : $80,111
2019/2020 : $5,000
|
Whelan, Timothy
McMaster University
Prospective cohort study evaluating risk of local recurrence following breast conserving surgery alone in low risk luminal A breast cancer
|
2017/2018 : $115,183
2018/2019 : $101,272
2019/2020 : $118,391
|